{
    "2019-03-05": [
        [
            {
                "time": "",
                "original_text": "乐普医疗:国内首家可降解支架获批,将贡献明显业绩",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "可降解支架",
                        "获批",
                        "业绩"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "上市至今暴涨10倍！医药并购之王！可股价狂跌56%,又是啥情况？",
                "features": {
                    "keywords": [
                        "暴涨",
                        "医药并购",
                        "股价狂跌"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "乐普医疗：整体业务维持较快增长 强烈推荐评级",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "业务增长",
                        "推荐评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "64股获券商买入评级 东诚药业目标涨幅达44.30%",
                "features": {
                    "keywords": [
                        "券商买入评级",
                        "东诚药业",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "科创板、A股其他板块与港股市场IPO制度及定价估值体系对比分析——会议纪要",
                "features": {
                    "keywords": [
                        "科创板",
                        "A股",
                        "港股",
                        "IPO制度",
                        "定价估值"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融",
                        "资本市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报:受益MSCI扩容,板块估值修复有望延续",
                "features": {
                    "keywords": [
                        "医药生物",
                        "MSCI扩容",
                        "估值修复"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}